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Abstract
Background: Many countries have implemented artemisinin-based combination therapy (ACT)
for the first-line treatment of malaria. Although many studies have been performed on efficacy and
tolerability of the combination arthemeter-lumefantrine (AL) or dihydroartemisinin-piperaquine
(DP), less is known of the effect of these drugs on gametocyte development, which is an important
issue in malaria control.
Methods and results: In this two-arm randomized controlled trial, 146 children were treated
with either AL or DP. Both groups received directly observed therapy and were followed for 28
days after treatment. Blood samples were analysed with microscopy and NASBA. In comparison
with microscopy NASBA detected much more gametocyte positive individuals. Moreover, NASBA
showed a significant difference in gametocyte clearance in favour of AL compared to DP. The
decline of parasitaemia was slower and persistence or development of gametocytes was
significantly higher and longer at day 3, 7 and 14 in the DP group but after 28 days no difference
could be observed between both treatment arms.
Conclusion: Although practical considerations could favour the use of one drug over another, the
effect on gametocytogenesis should also be taken into account and studied further using molecular
tools like NASBA. This also applies when a new drug is introduced.
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Background
In response to widespread resistance of Plasmodium falci-
parum parasites to the commonly used drugs chloroquine
(CQ) and sulphadoxine-pyrimethamine (SP), many Afri-
can countries recently adopted artemisinin-based combi-
nation therapy (ACT) as first-line treatment for
uncomplicated malaria. The combination artemether-
lumefantrine (AL) proved to be highly effective and well-
tolerated in several studies in Africa [1-5]. Disadvantages
of this drug combination are the twice-daily dosing and
the fact that it should be administered with a fat-rich meal
[6-8] or at least a cup of soya milk [2]. In Uganda, in an
area of intense malaria transmission, recurrence of parasi-
taemia within 28 days occurred in 29% of AL treated
patients, in 8.9% adjusted by genotyping, indicating
recrudescence [4].
Another ACT, dihydroartemisinin combined with piper-
aquine (DP), which was originally developed in China, is
increasingly used in Southeast Asia [9,10]. Piperaquine is
an orally active bisquinoline with a half-life elimination
time of 2.5–4 weeks [9]. The drug is structurally related to
CQ, but still active against highly CQ-resistant P. falci-
parum strains [1,11]. This relatively inexpensive drug was
well tolerated and highly effective in Southeast Asia
[1,7,11-13] as was the case in two studies in Africa [4,14].
Consequently, both AL and DP are considered to be
amongst the most promising artimisinin-based drugs
[4,14]. Artemisinin-based drugs also act on gametocytes
and thus on transmission, at least in low transmission
areas [15-17]. In high transmission areas of Africa, not
much information is yet available on gametocytaemia
after ACT treatments and on possible influence on trans-
mission. In a comparative study of AL and DP in Uganda,
the appearance of gametocytes in those who did not have
gametocytes at the start of treatment was lower from day
15 to day 42 of follow up in those treated with DP than in
those treated with AL [4]. A limitation of this study was
the fact that gametocytaemia was assessed by microscopic
examination only. It has recently been shown that sub-
microscopic gametocyte densities may significantly con-
tribute to the transmission of malaria [18].
Adequate assessment of gametocytaemia is important.
Quantitative nucleic sequence based amplification tech-
nique (QT-NASBA) has been shown to be much more
sensitive for the detection of gametocytes than micros-
copy [3,18-20]. In this study, the post-treatment preva-
lence of gametocytes in children in Mbita, western Kenya
was assessed, after treatment with AL and DP. Microscopy
and QT-NASBA for the quantification of gametocytaemia
were compared and effectiveness of both drugs regarding
clinical symptoms, clearance of parasites and tolerability
was assessed.
Materials and methods
Study site and population
The study was conducted in Mbita, western Kenya, at the
shores of Lake Victoria during the high malaria transmis-
s i o n  s e a s o n  o f  A p r i l - J u l y  2 0 0 7 .  M b i t a ,  i s  a n  a r e a  w i t h
highly variable transmission that depends on the local
environmental circumstances that can support mosquito
conditions. The EIR is calculated to be 6 infectious bites
per person per month [21]. Children (6 months-12 years
of age) visiting the out-patient clinic of the health centre
and diagnosed with uncomplicated malaria were
included after informed consent from parents or guardi-
ans. Inclusion criteria were: uncomplicated P. falciparum
malaria with initial parasitaemia between 1,000 and <
200,000 parasites/μl blood, axillary temperature ≥ 37.5°C
(measured with a digital thermometer) or a history of
fever. Children with severe malaria, mixed infection or
other underlying illness were excluded from the study. In
total 146 children were recruited for the present study.
Ethical approval for this study was obtained from appro-
priate local authorities and The Kenya Medical Research
Institute (KEMRI, Nairobi, Kenya) Ethical Steering Com-
mittee (SSC protocol No 948). The trial was registered as
an International Standard Randomized Controlled Trial
at current controlled trials (ISRCTN36463274).
Study design and treatment
Following diagnosis (at day 0), the patients were ran-
domly allocated to one of the two treatment groups fol-
lowing a computer generated randomization list. One
group was assigned DP (Sigma-Tau, Italy) once per day for
three days. One tablet of the study drug contained 20 mg
of dihydroartemisinin and 160 mg of piperaquine (paedi-
atric formulation). Treatment was according to body
weight as follows: children between 4–7 kg received half a
tablet per dose, those between 7–13 kg 1 tablet, 13–24 kg
2 tablets per dose and children between 24–35 kg 4 tab-
lets. The other group was assigned to AL (Novartis
Pharma, Switzerland). Each tablet contained 20 mg arte-
mether and 120 mg lumefantrine. Patients received treat-
ment according to bodyweight; i.e. children between 5–
14 kg received one tablet per dose, those between 15–24
kg two tablets and those between 25–34 kg received three
tablets per dose. Doses were given twice daily. All treat-
ments were given with a glass of milk under direct super-
vision at the clinic or, for the 2nd dose of AL, at home.
Outcomes: efficacy
Efficacy was assessed using the WHO in vivo test with a
follow-up period of 28 days [22]. At enrollment (day 0) a
full clinical examination was performed; information was
recorded on a case record form. At initial diagnosis (day
0) and during follow-up (day 1, 2, 3, 7, 14, and 28), finger
prick blood samples were collected for microscopy, meas-
urement of haemoglobin level and molecular analysis.Malaria Journal 2008, 7:237 http://www.malariajournal.com/content/7/1/237
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Haemoglobin was measured with Hemocue 201+ ana-
lyser and cuvettes (HemoCue diagnostics B.V. Waarle, The
Netherlands). Response to treatment was measured and
defined according to WHO guidelines [22].
Patients showing complications or treatment failure were
treated with appropriate supportive therapy. Children
developing danger signs or severe malaria on day 1 or 2 of
the study were withdrawn from the study, referred to the
hospital, and given alternative treatment. Adverse events
were recorded on the case record forms. An AE was
defined as an unfavourable and unintended symptom,
sign or disease. A serious adverse event (SAE) was defined
as a symptom or sign that is temporally associated with
the drugs administered to the patient that is life threaten-
ing or results in hospitalization, permanent and signifi-
cant disability or death. SAE's were immediately reported
to the ethical committee of KEMRI and the drug safety
department of Sigma-Tau, Italy.
Outcomes: parasite clearance and gametocyte dynamics
Parasite clearance and gametocyte dynamics were assessed
microscopically as well as with quantitative nucleic acid
sequence based amplification assay, QT-NASBA.
Microscopy
Giemsa-stained thick and thin smears were prepared
according to WHO guidelines. Two independent experi-
enced microscopists, who were blinded to the treatment
and clinical status of the patient, examined the smears for
the presence of parasites and identified the observed par-
asite species. Parasitaemia was determined by counting
the number of parasites against 200 leukocytes for the
asexual stages (assuming that there are 8,000 leukocytes/
μl blood). The presence of gametocytes was examined
against 500 leukocytes.
QT-NASBA
Finger prick blood (50 ul) for NASBA analysis was col-
lected on Whatman 903 filter paper (Whatman interna-
tional Ltd. Maidston, United Kingdom) and air-dried at
room temperature. Nucleic acid extraction was performed
as previously described by Boom et al [23]. Real-time 18S
rRNA QT-NASBA was applied to study asexual parasite
clearance below microscopical threshold [20]. In order to
quantify the number of parasites in blood, a 10 fold serial
dilution of 106 to 10 in vitro cultured parasites/ml was
used as reference and processed and analysed with
NASBA. Furthermore, to assess prevalence of gametocytes
below the detection limit of microscopy, QT-NASBA tar-
geting Pfs25 mRNA as described by Schneider et al [20]
was used on blot spots collected during follow-up.
Genotyping
In order to discriminate between re-infection (RI) and
recrudescence (RE), merozoite surface protein 1 and 2
(msp1 and msp2) and glutamate rich protein (GLURP)
genotyping was performed as described by Snounou [24]
on blood spots obtained at primary (day 0) and secondary
infection (time point of re-occurrence). Blood spots were
collected on Whatman 903 filter paper (Whatman inter-
national Ltd. Maidston, United Kingdom) and air-dried at
room temperature for PCR analysis. DNA was isolated as
described by Boom et al [23]. Molecular analysis was per-
formed at Royal Tropical Institute, Amsterdam and was
done blinded from the treatment that was given to the
patients.
Sample size and statistical analysis
The aim of the study was to compare gametocytaemia
after AL and DP and to compare assessment of gametocy-
taemia by microscopical examination versus QT-NASBA
All data were entered in excel and analysed with SPSS for
windows (version 12.0). Parasite densities were analysed
after natural log-transformation. Where appropriate, pro-
portions were compared with the χ2-test and means were
compared with the one-way ANOVA or Student t-test. A
simplified trapezoid area under the curve (AUC) analysis
using gametocyte data from days 0, 3, 7, 14 and 28, as a
surrogate for the infectiousness of the participants in the
different treatment groups, was performed.
Results
Patient recruitment
In total 1882 cases suspected of uncomplicated malaria
were screened for eligibility into the study during an 8-
week recruitment period in April and May 2007. 1,736
children were excluded because they did not meet the
inclusion criteria (Figure 1). 146 patients fulfilling the
inclusion criteria entered the study; 73 were randomly
allocated to the DP arm and 73 to the AL arm. Both study
groups were comparable at baseline for their demograph-
ical and clinical characteristics and parasite densities
(Table 1). On completion of follow up (day 28) data of
134 patients (92%) were available for analysis.
Twelve patients did not reach the study endpoint. Seven
patients were lost during follow up, one was unable to
take oral medication, one developed severe anaemia, one
did not receive the proper drugs, one withdrew from the
study and one patient died.
Treatment outcome
There were no early treatment failures during the first
three days of follow up. Only one patient in the AL arm
had a recurrent parasitaemia (43,880 parasites/μl) at day
28 of follow up. Genotyping analysis revealed that this
patient had a reinfection with P. falciparum. All other 133Malaria Journal 2008, 7:237 http://www.malariajournal.com/content/7/1/237
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patients who completed follow-up had an adequate clini-
cal and parasitological response. After one day of treat-
ment, over 90% of the patients had no microscopically
detectable asexual parasites. In the AL group no parasites
could be detected with microscopy in any of the patients
at day two. One patient was still microscopically positive
at day two in the DP group with 40 parasites/μl, but this
patient was also microscopically negative at day 3. The
Table 1: Baseline characteristics of patients included in the study at the time of enrollment in the study
Characteristic DHA-PQP (n = 73) ALN (n = 73)
Sex ratio male:female 33:40 40:33
Age (in months), median (IQR) 60 (44) 52 (44)
Body weight, mean kg (range) 17.62 (6–37) 17.32 (6–42)
Temperature, mean °C ± SD 38.1 ± 0.99 37.8 ± 0.73
Haemoglobin mmol/L ± SD 6.33 ± 1.29 6.28 ± 1.27
Parasites/μl geometric mean (range) as determined by microscopy 12145 (1000–72640) 13379 (1080–72000)
Schematic representation and flowchart of the study Figure 1
Schematic representation and flowchart of the study.Malaria Journal 2008, 7:237 http://www.malariajournal.com/content/7/1/237
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parasite reduction ratios at 48 hours reproduction cycle
(parasite count on admission/parasite count at 48 hours)
was 8.96 * 105 at 48 hours for the AL treatment and 2.06
* 104 at 48 hours for the DP treatment.
NASBA was also applied to monitor parasite dynamics
below sub-microscopical level. Humidity in some of the
filter papers degraded the RNA in the blood spots of some
of the samples. This led to several extraction failures. In
order to have a clear picture of parasite dynamics only
those series with a full range of follow-up samples, i.e. 56
DP and 54 AL treated patients, were analysed. Both treat-
ment arms showed a steep decline in parasitaemia from
the day of enrollment (day 0) to day 1; 62% reduction
after DP treatment and 89% reduction in the AL arm. At
day 2, the level of parasitaemia was reduced to 1.2% in the
AL group and 2.75% in the DP group.
Hb convalescence, fever clearance and adverse events
At baseline Hb levels in both treatment groups were com-
parable (Table 1). At day 28 all groups had a significant
increase of Hb however no significant difference between
the treatments on the Hb convalescence was found. Final
mean Hb levels were 7.15 mmol/l ± 1.07 for the DP treat-
ment group and 6.79 mmol/l ± 1.24 for the AL group. A
possible influence of anaemia on gametocyte carriage at
enrollment was not observed in the present study (p >
0.05).
Fever clearance was defined as the time from receiving the
assigned treatment to the time a normal body temperature
was recorded (≤ 37.5°C), in study cases who presented
with fever. Fever clearance was rapid in both study groups.
On day 1, 10 cases (13.7%) in the DP group presented
with fever and six cases (8.2%) were observed in the AL
group. In the DP group fever was observed on day 2 in
four cases (5.5%) and three cases (4.1%) on day 3. In the
AL group cases with fever also presented on day 2 (12
study subjects, 16.4%) and on day 3 (two individuals,
2.7%). Fever was not observed during follow-up after day
7, with the exception of the child that presented with a P.
falciparum reinfection on day 28 in the AL group and the
child that developed broncho-pneumonia (case presented
below). Furthermore the presence of fever at recruitment
was no predictor for gametocyte carriage (p > 0.05)
Most adverse events were mild, self limiting and consist-
ent with symptoms of malaria. There was no significant
difference between the two study groups (Table 2). One
patient died. The child (63 months) had been ill for two
weeks prior to presentation at the clinic. Plasmodium falci-
parum infection with parasitaemia of 20,120 parasites/μl
was diagnosed. There was a fever (38.6°C), but there were
no other complaints and no signs of severe anaemia (Hb:
6.4 mmol/L). On day 3, there were no signs of illness. On
day 7, the child presented with fever (38.6°C), cough and
complaints of anorexia. There was no history of signifi-
cant illness or allergies. After examination (microscopy
was negative for malaria parasites), broncho-pneumonia
was diagnosed and the child was treated with oral phe-
noxymethylpenicillin for five days and Paracetamol
syrup. On day 14, the child did not attend the follow-up
visit, the parents reported that the child died a day before
in a local health post. The event was assessed as unrelated
to the study drug. Autopsy was not performed.
Gametocyte dynamics
The presence of gametocytes in clinical samples was
assessed by microscopy and NASBA and is presented in
Table 3. At the start of the study, three patients in the DP
arm (4.5%) and six patients in the AL arm (9.0%) carried
microscopically detectable gametocytes. Microscopical
follow-up of the presence of gametocytes during the
whole study period revealed that in total 39 samples (dis-
tributed over 13 patients) in the DP arm and 18 samples
(distributed over nine patients) in the AL arm carried
gametocytes (not significantly different). It was observed
that the microscopical detection of gametocytes in blood
slides during the study was subjected to fluctuations (for
example a case positive on day 0, negative on day 1 and
subsequently again positive at day 3), which is probably
due to the fact that gametocytes circulate at low levels.
However, on day 7, three patients in the DP group and 1
in the AL group showed gametocyte positive slides for the
first time. On day 28, in none of the cases gametocytes
were observed by microscopy. There was no difference
between children older than 60 months and younger as
regards carriage of gametocytes and density.
NASBA analysis on 56 DP treated subjects and 54 AL
treated subjects detected strikingly more gametocyte carri-
ers at the start of the study compared to microscopy; i.e.
22 study subjects in the DP arm (39.3%) and 21 in the AL
(38.9%) were harbouring gametocytes before. The pfs25
NASBA revealed that 34 cases (60.7%) were gametocyte
positive in the DP group on day 3, of which 13 cases were
newly identified compared to day 0. In contrast, a signifi-
cantly lower number of patients (20; 37%) were gameto-
Table 2: Summary of adverse events recorded during the study
Adverse event DHA-PQP ALN P-value
Headache 43 (58.9%) 37 (50.7%) 0.318
Abdominal pain 25 (32.4%) 26 (35.6%) 0.862
Weakness 19 (26.0%) 30 (41.1%) 0.035
Anorexia 8 (10.9%) 10 (13.7%) 0.439
Diarrhea 9 (12.3%) 7 (9.6%) 0.785
Cough 16 (21.9%) 17 (23.3%) 0.843
Vomiting 11 (15.1%) 9 (12.3%) 0.806
Pruritis 4 (5.5%) 3 (4.1%) 0.698Malaria Journal 2008, 7:237 http://www.malariajournal.com/content/7/1/237
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cyte positive in the AL treatment group on day 3, of which
six new cases. This trend was also observed on day 7: the
DP arm had 33 (58.9%) gametocyte positive samples,
whereas the AL treated group had a significantly lower
number of gametocyte positive samples (11, 20.3%).
However on day 14 (AL: 12 positive [22.2%], six new; DP:
17 [30.4%], five new) and day 28 (AL: 5 positive [9.3%],
no new cases; DP: 8 [14.3%], no new cases) of follow-up
no significant difference in gametocyte carriage was
observed between both treatment groups. The AUC (day 0–
28) of the two treatment groups was calculated to be 20.0
infectious persons/day for the DP treatment arm and 10.5
infectious persons/day for the AL treatment arm. Stratify-
ing the data for age under and above 60 months showed
no difference in either of the groups.
Discussion
Several studies have analysed the efficacy and tolerability
of AL and DP and all show very good results
[1,4,6,7,12,14,25]. In the present study, the two drugs
showed to be similar with respect to effectiveness and tol-
erability compared to other studies. However, most of
these studies have a follow up of 42 days which makes a
direct comparison of the results difficult. No adverse
events other than those related to malaria itself were
observed in the current study, which is in line with other
reports. In the present study, all children experienced hae-
moglobin convalescence without difference between the
two treatment arms, in contrast to the study of Kamya et
al, who found a greater increase in the DP treated patients
[4]. The difference in follow-up time and the numbers of
patients included in both studies may be responsible for
this difference. Further studies with comparable study
length should be done to give an answer to these discrep-
ancies.
The effects on gametocytaemia and possibly malaria
transmission deserve further study. Whereas asexual para-
sites were cleared in three days after the initiation of the
two treatment schedules, gametocytaemia appeared dif-
ferent when assessed by microscopy as well as with
NASBA. Gametocytes were present in low numbers
throughout follow-up in both study groups. Artemisinin
derivatives have in general a negative effect on gametocyte
development and survival and thus influence malaria
transmission, at least in low transmission areas [15-17].
In this study, the actual infectiousness of the remaining
gametocyte populations in both treatment arms was not
assessed; the presence of gametocytes does not necessarily
mean that they actually contribute to transmission. Sev-
eral studies have shown that gametocytes persist in a large
population of previously infected and treated children
[5,19,26,27]. A large proportion of these carriers has a
parasite load below microscopical detection limit, a load
that can be detected with molecular assays like NASBA.
Patients with submicroscopic parasite densities may still
be infectious to mosquitoes and may contribute to trans-
mission [14,19], as confirmed with membrane feeding
experiments [18,28]. Studies that include reduction of
transmission as a component of efficacy of drugs, thus
need to incorporate highly sensitive molecular assays to
reliably assess gametocyte densities.
The present study showed a limited effect of DP on game-
tocyte development in comparison with AL when a sensi-
tive tool like NASBA is used for gametocyte detection,
which could limit the usefulness of DP to areas with low
transmission but this finding should be further investi-
gated in larger studies in different study sites with differ-
ent transmission intensities. It is not clear if plasma
concentrations of dihydroartemisinin in the blood could
Table 3: Occurrence of gametocytes as detected by microscopy or NASBA in the different study groups at the start of the study and 
during subsequent follow-up.
Gametocyte positive samples Day 0 Day 1 Day 2 Day 3 Day 7 Day 14 Day 28
DP group microscopy (n = 67)
Total number of positive cases 3 7 7 10 7 5 0
N u m b e r  o f  n e w  c a s e s  o b s e r v e d 52030 0
DP group Nasba (n = 56)
Total number of positive cases 22 34a 33a 17 8
Number of new cases observed 13 8 5 0
AL group microscopy (n = 67)
T o t a l  n u m b e r  o f  p o s i t i v e  c a s e s 633321 0
N u m b e r  o f  n e w  c a s e s  o b s e r v e d 11010 0
AL group Nasba (n = 54)
Total number of positive cases 21 20 11 12 5
Number of new cases observed 6 4 6 0
a Number of gametocyte carriers detected with NASBA is significantly higher in the DP treated group compared to the AL treated group.Malaria Journal 2008, 7:237 http://www.malariajournal.com/content/7/1/237
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play a role. Dihyrodartemisinin is the major and the active
metabolite of artemether. So far, no studies have been per-
formed that compare the plasma levels of dihydroartem-
isinin when given as such or after administration of
artemether and subsequent metabolisation. This should
be further investigated together with effect on gametocy-
togenesis, which should incorporate a sensitive detection
tool for gametocytes such as NASBA.
The effect that drugs can have on gametocyte clearance as
measured with NASBA could have some implications for
the introduction drugs and especially the introduction of
new drugs. This study showed that with sensitive detec-
tion tools a difference in parasite clearance can be
observed but these results should be confirmed in larger
studies and in other study areas with different malaria
transmission intensities. Transmission intensity varies sig-
nificantly in the different African countries and within a
country high and low transmission areas can often be
identified. Malaria endemic countries generally have a
national malaria drug policy for the whole country.
Although this is logical from a practical and logistical
point of view, it may not be the best approach for effective
malaria control. It could, therefore, be more effective if a
country develops specific drug policies to suit regional
instead of national requirements.
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